Lazertinib improves the efficacy of chemotherapeutic drugs in ABCB1 or ABCG2 overexpression cancer cells in vitro, in vivo, and ex vivo

Abstract excerpt

Multidrug resistance (MDR) is the major cause of chemotherapy failure, which is usually caused by the overexpression of ATP-binding cassette (ABC) transporters such as ABCB1 and ABCG2. To date, no MDR modulator has been clinically approved. Here, we found that lazertinib (YH25448; a novel third-generation tyrosine kinase inhibitor [TKI]) could enhance the anticancer efficacy of MDR transporter substrate...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cholangiocarcinoma and Gallbladder Cancer Studies
• Share to Drug Transport and Resistance Mechanisms
• Share to Pancreatic and Hepatic Oncology Research